



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

TO: Primary Clinical Research Associates

FROM: Janis Wobschall
Protocol Development Coordinator

DATE: September 1, 2006

SUBJECT: N0272, Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

The Event Monitoring Continuation Form has been revised: "Relationship to Study Medication" column was added.